PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance

Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) have enabled some patients with cancer to experience durable, complete treatment responses; however, reliable anti–PD-(L)1 treatment response biomarkers are lacking. Our research...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Changsheng, Ren, Shengxiang, Chen, Yaqi, Liu, Anyi, Wu, Qi, Jiang, Tao, Lv, Panjing, Song, Da, Hu, Fuqing, Lan, Jingqing, Sun, Li, Zheng, Xue, Luo, Xuelai, Chu, Qian, Jia, Keyi, Li, Yan, Wang, Jun, Zou, Caicun, Hu, Junbo, Wang, Guihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219601/
https://www.ncbi.nlm.nih.gov/pubmed/37235656
http://dx.doi.org/10.1126/sciadv.ade4186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219601/
https://www.ncbi.nlm.nih.gov/pubmed/37235656
http://dx.doi.org/10.1126/sciadv.ade4186

Ejemplares similares